Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

117 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
Wang X, Ding J, Meng LH. Wang X, et al. Among authors: meng lh. Acta Pharmacol Sin. 2015 Oct;36(10):1170-6. doi: 10.1038/aps.2015.71. Epub 2015 Sep 14. Acta Pharmacol Sin. 2015. PMID: 26364801 Free PMC article. Review.
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.
Meng LH, Liao ZY, Pommier Y. Meng LH, et al. Curr Top Med Chem. 2003;3(3):305-20. doi: 10.2174/1568026033452546. Curr Top Med Chem. 2003. PMID: 12570765 Review.
Emerging cancer therapeutic opportunities target DNA-repair systems.
Ding J, Miao ZH, Meng LH, Geng MY. Ding J, et al. Among authors: meng lh. Trends Pharmacol Sci. 2006 Jun;27(6):338-44. doi: 10.1016/ Epub 2006 May 11. Trends Pharmacol Sci. 2006. PMID: 16697054 Review.
Salvicine, a novel topoisomerase II inhibitor, exerts its potent anticancer activity by ROS generation.
Meng LH, Ding J. Meng LH, et al. Acta Pharmacol Sin. 2007 Sep;28(9):1460-5. doi: 10.1111/j.1745-7254.2007.00698.x. Acta Pharmacol Sin. 2007. PMID: 17723179 Review.
Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain.
Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L, Zhang X, Ding J. Qin Y, et al. Among authors: meng l. Mol Cancer Ther. 2007 Sep;6(9):2429-40. doi: 10.1158/1535-7163.MCT-07-0147. Mol Cancer Ther. 2007. PMID: 17876042
Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species.
Lu JJ, Meng LH, Cai YJ, Chen Q, Tong LJ, Lin LP, Ding J. Lu JJ, et al. Among authors: meng lh. Cancer Biol Ther. 2008 Jul;7(7):1017-23. doi: 10.4161/cbt.7.7.6035. Epub 2008 Apr 4. Cancer Biol Ther. 2008. PMID: 18414062
The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo.
Ma J, Xin X, Meng L, Tong L, Lin L, Geng M, Ding J. Ma J, et al. Among authors: meng l. PLoS One. 2008;3(11):e3774. doi: 10.1371/journal.pone.0003774. Epub 2008 Nov 20. PLoS One. 2008. PMID: 19020661 Free PMC article.
S9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeleton.
Zhang C, Yang N, Yang CH, Ding HS, Luo C, Zhang Y, Wu MJ, Zhang XW, Shen X, Jiang HL, Meng LH, Ding J. Zhang C, et al. Among authors: meng lh. PLoS One. 2009;4(3):e4881. doi: 10.1371/journal.pone.0004881. Epub 2009 Mar 18. PLoS One. 2009. PMID: 19293927 Free PMC article.
New microtubule-inhibiting anticancer agents.
Chen SM, Meng LH, Ding J. Chen SM, et al. Among authors: meng lh. Expert Opin Investig Drugs. 2010 Mar;19(3):329-43. doi: 10.1517/13543780903571631. Expert Opin Investig Drugs. 2010. PMID: 20141350 Review.
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and induces apoptosis in c-MYC-overexpressing tumor cells.
Lu JJ, Meng LH, Shankavaram UT, Zhu CH, Tong LJ, Chen G, Lin LP, Weinstein JN, Ding J. Lu JJ, et al. Among authors: meng lh. Biochem Pharmacol. 2010 Jul 1;80(1):22-30. doi: 10.1016/j.bcp.2010.02.016. Epub 2010 Mar 3. Biochem Pharmacol. 2010. PMID: 20206143
117 results
Jump to page